Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes for Therapy of Relapsed Leukemia After Allogeneic Stem Cell Therapy
- AML (any type except M3) or CIVIL in blast crisis with greater than or equal to 20%
bone marrow blasts at the time of related donor marrow or stem cell transplantation
or at relapse post transplant.
- Willing to undergo a skin biopsy and either a leukodepletion apheresis or an
additional marrow aspiration.
- Stem cell or marrow donor willing to have apheresis for T-Cell collection.
- Written voluntary informed consent must be obtained from patient and donor.
- Medical, social or psychologic factors which would prevent the patient from receiving
or cooperating with the full course of therapy or understanding the informed consent
- AML French-American-British (FAB) subtype M3.
Type of Study:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Participant Toxicity Levels
Participant toxicity of infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell transplants.
Outcome Time Frame:
From stem cell transplant baseline to 30 plus days post transplant.
Elizabeth J. Shpall, MD
UT MD Anderson Cancer Center
United States: Food and Drug Administration
- Leukemia, Myelocytic, Acute
- Dendritic cells
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
|M.D. Anderson Cancer Center
||Houston, Texas 77030